PB-007-3

PB-007-3 is a preclinical small molecule drug candidate developed by Pan-Biome Pharmaceuticals. It is designed to modulate the levels of several key cytokines, specifically targeting Interleukin-10 (IL-10), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6). By balancing pro-inflammatory (TNF-α, IL-1β, IL-6) and anti-inflammatory (IL-10) signals, the compound aims to treat various inflammatory diseases. Beyond traditional therapeutic indications, Pan-Biome is investigating PB-007-3 for its potential to extend healthspan and lifespan, likely by addressing chronic low-grade inflammation associated with aging (inflammaging).